Who are Azelastine - intranasal application's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Antihistamine Cetirizine Hydrochloride, diphenhydramine/phenylephrine/cocoa; placebo; dextromethorphan, Olopatadine Nasal Spray, Morphine-Promethazine, Ciclesonide & Levocetirizine, Fluticasone/Azelastine nasal spray.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/azelastine-intranasal-application.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Azelastine - intranasal application — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Azelastine - intranasal application (Azelastine - intranasal application) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Selective H1-receptor antagonist (intranasal antihistamine). Area: Allergy/Immunology.

marketed Selective H1-receptor antagonist (intranasal antihistamine) H1 histamine receptor Allergy/Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Azelastine - intranasal application (Azelastine - intranasal application) — Association Asthma, Bulgaria. Azelastine is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses in the nasal mucosa.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Azelastine - intranasal application TARGET	Azelastine - intranasal application	Association Asthma, Bulgaria	marketed	Selective H1-receptor antagonist (intranasal antihistamine)	H1 histamine receptor
Antihistamine Cetirizine Hydrochloride	Antihistamine Cetirizine Hydrochloride	Goldman, Butterwick, Fitzpatrick and Groff	marketed	H1-receptor antagonist (second-generation antihistamine)	H1 histamine receptor
diphenhydramine/phenylephrine/cocoa; placebo; dextromethorphan	diphenhydramine/phenylephrine/cocoa; placebo; dextromethorphan	Montefiore Medical Center	marketed	Combination cold/cough/allergy remedy	H1 histamine receptor (diphenhydramine); alpha-1 adrenergic receptor (phenylephrine); NMDA receptor and sigma-1 receptor (dextromethorphan)
Olopatadine Nasal Spray	Olopatadine Nasal Spray	ORA, Inc.	marketed	Selective H1-receptor antagonist / mast cell stabilizer	H1 histamine receptor
Morphine-Promethazine	Morphine-Promethazine	Tel-Aviv Sourasky Medical Center	marketed	Opioid analgesic combination	Mu-opioid receptor (morphine); H1 histamine receptor (promethazine)
Ciclesonide & Levocetirizine	Ciclesonide & Levocetirizine	Handok Inc.	marketed	Inhaled corticosteroid + selective H1-receptor antagonist combination	Glucocorticoid receptor (ciclesonide); H1 histamine receptor (levocetirizine)
Fluticasone/Azelastine nasal spray	Fluticasone/Azelastine nasal spray	University of Chicago	marketed	Intranasal corticosteroid/antihistamine combination	Glucocorticoid receptor; H1 histamine receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Selective H1-receptor antagonist (intranasal antihistamine) class)

Association Asthma, Bulgaria · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Azelastine - intranasal application — Competitive Intelligence Brief. https://druglandscape.com/ci/azelastine-intranasal-application. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing